© 2017 Pharmstandard Ventures

Neon Therapeutics
Cambridge, MA, USA
Year of Investment: 2016
IPO in June, 2018

Neon Therapeutics
Cambridge, MA, USA
Year of Investment: 2016
IPO in June, 2018
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. Neon's lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute.

For more information, please visit:
www.neontherapeutics.com

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally